Phibro Animal Health Corporation (PAHC) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

67OpportunityDD: May 18, 2026Analyst: 73

paidPrice at analysis date

USD 34.4 (18/05/2026)

domainMkt cap

$1.39B

pie_chartShares

40.53M

candlestick_chart52W

$19.00-$60.08

trending_downShort interest

5.9%

MEDIUMNASDAQHealth Care1800 employeesFounded 1946

Verdict: MEDIUM RISK — Post-correction VALUE setup with regulatory overhang

Mid-single-digit-growth animal health franchise re-rated lower by 42% in 5 weeks after Brazil antimicrobial regulatory change overshadowed a strong Q3 beat-and-raise. At $34.4 the stock trades at 8.2x EV/EBITDA fw vs 11–16x for peers, implying ~25% asymmetric upside to a base FV of $45. Persistent CEO-linked insider selling and 3.3x net leverage keep this a "show-me" story, not a clean compounding buy.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-05-18

Phibro Animal Health Corporation (PAHC)

Animal Health Pharmaceuticals · NASDAQ · Teaneck, NJ

"Re-rated value with leverage overhang — modest base upside, asymmetric to upside vs bear at 2.7:1"

VALUE re-rating FY26 guidance raised Brazil reg. overhang Net leverage 3.3x Persistent insider selling Zoetis MFA integration

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — EV/EBITDA peer-multiple (FY26E)

Fair value base case

USD 45.0

Range: USD 26.0-USD 56.0

Price at analysis date: USD 34.4 (18/05/2026)

Base upside/downside: +31%

Methodology: EV/EBITDA peer-multiple on FY26E adj. EBITDA midpoint ($251M, raised May 6, 2026). Probability-weighted FV: 0.25×$56 + 0.50×$45 + 0.25×$26 = $43.4 , implying +26% expected upside vs $34.4. Risk/reward 2.7:1 (bull +62% / bear −23%). Numbers derived bottom-up from peer median minus discrete leverage/region/integration discounts — no reverse-engineering from a target price. ⚠️ Not investment advice.

Component	Assumption	USD/share
Animal Health segment EV	$225M FY26E EBITDA × 11.0x (Elanco 11x / Virbac 12x median; Zoetis 16x excluded as premium pure-play)	+$61.1
Mineral Nutrition + Performance Products EV	$26M FY26E segment EBITDA × 6.0x (commodity-style ag-chem multiple)	+$3.7
Net debt (Mar 31, 2026)	$731M total debt − $74M cash = $657M / 40.53M sh.	−$16.2
Brazil regulatory reserve	−5% haircut on Animal Health segment EV (LatAm legacy MFA exposure)	−$3.0
Integration / execution discount	−$0.6/sh for Zoetis-MFA integration risk (one-time costs + synergy ramp lag)	−$0.6
Base case fair value	Sum: 61.1 + 3.7 − 16.2 − 3.0 − 0.6 = $45.0 (rounded)	≈ $45.0

Bull

$56

Probability: 25%

Brazil clarification favorable (or limited scope); FY27 guidance raised on Zoetis-MFA synergies; EBITDA $265M × 11.5x; multiple expansion as leverage falls below 3.0x.

Base

$45

Probability: 50%

FY26 guidance delivered ($251M EBITDA); Brazil headwind modest (−$10–15M impact); multiple stays at 10–11x; sentiment normalizes by FY27 guidance update.

Bear

$26

Probability: 25%

Brazil framework tightens further; legacy MFA growth flat-to-down; FY27 EBITDA $225–230M × 7.5x; covenant pressure if leverage drifts to 3.8x+; dividend at risk.

Methodology: Methodology: EV/EBITDA peer-multiple on FY26E adj. EBITDA midpoint ($251M, raised May 6, 2026). Probability-weighted FV: 0.25×$56 + 0.50×$45 + 0.25×$26 = $43.4 , implying +26% expected upside vs $34.4. Risk/reward 2.7:1 (bull +62% / bear −23%). Numbers derived bottom-up from peer median minus discrete leverage/region/integration discounts — no reverse-engineering from a target price. ⚠️ Not investment advice. Not investment advice.

warning

🚨 Brazil antimicrobial regulatory reset triggered −42% drawdown despite Q3 beat-and-raise

On May 7, 2026 Phibro reported Q3 FY26 net sales $383.5M (+10% YoY), adj. EBITDA $60.8M (+11%) and raised FY26 guidance — yet the stock fell from ~$59.6 (Apr 13) to $34.4 (May 15 close). Catalyst: Brazil regulatory framework change for antimicrobials forces Phibro to rethink its strategy in a material LatAm market. Layered on top: Citi cut price target $62 → $44 on May 14; CEO-linked BFI Co. LLC sold ~$1.0M in stock May 5–7 in $47–$58 range under a pre-set 10b5-1 plan. The fundamentals print is good; the multi-month sentiment overhang is real.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

5.9%

~1.2M shares short of float (~40.5M outstanding). Up 10.3% vs prior period. Moderate — signals skepticism on Brazil/integration but no squeeze setup.

🟢 Share dilution (1Y)

~+0.5%

From ~40.3M to 40.53M Class A shares. Minimal — mostly equity comp vesting. No primary issuance or shelf utilization.

🟡 Buyback / Dividend

$0.12/q

Quarterly dividend $0.12/share declared May 5, 2026 (~1.4% yield at $34.4). No active buyback — capital priority is Zoetis-MFA integration + deleveraging.

Short Interest — context

PAHC — 5.9%

5.9%

Insider selling — material flag: BFI Co. LLC (entity controlled by President/CEO Jack Bendheim) sold ~18,608 shares May 5–7, 2026 at $47–$58 weighted-average prices (~$1.0M total) under a pre-arranged Rule 10b5-1 plan adopted Dec 11, 2025. The CEO sold a further 110,842 shares in Feb 2026, $272K in Mar, $385K in Apr (one director sold $569K). Programmatic — but the pace is high and cumulative over 12 months exceeds ~$3–4M from insiders. The 10b5-1 cover removes legal risk but does not remove the signal.

$Financial analysis — FY26 (June fiscal year)

FY26E net sales

$1.47B

+12% YoY (Zoetis-MFA accretion)

FY26E adj. EBITDA

$251M

17.1% margin (+90 bps YoY)

FY26E adj. EPS

$3.04

vs $2.45 FY25 (+24%)

Net leverage (Mar-26)

3.3x

Covenant 4.75x — cushion adequate

Item	FY24	FY25	FY26E	FY27E	Guidance FY26
Net sales ($M)	1,025	1,310	1,467	1,520	1,460–1,475
Adj. EBITDA ($M)	132	198	251	265	247–255
Adj. EBITDA margin	12.9%	15.1%	17.1%	17.4%	—
Adj. diluted EPS ($)	1.10	2.45	3.04	3.30	2.98–3.10
GAAP diluted EPS ($)	0.45	1.60	2.35	2.65	2.25–2.44
Total debt ($M)	485	731	705	665	—
Cash ($M)	110	74	95	120	—
Net leverage (x EBITDA)	2.8x	3.3x	2.8x	2.5x	—

FY24/FY25 actuals; FY26E reflects raised guidance midpoints (May 6, 2026); FY27E is internal estimate. Total debt step-up driven by $297M Zoetis-MFA acquisition (closed Oct 31, 2024) financed via term loan add-on.

Quarterly dynamics — last 5 quarters
Metric	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
Revenue ($M)	290	336	351	358	383.5
YoY growth	+8%	+22%	+25%	+18%	+10%
Adj. EBITDA ($M)	42	52	61	62	60.8
Adj. EBITDA margin	14.5%	15.5%	17.4%	17.3%	15.9%
Diluted EPS ($)	0.42	0.55	0.78	0.74	0.59

Financial position and sustainability

Net leverage vs covenant (4.75x)

3.3x

Liquidity ($M cash + undrawn)

$274M

FY26E adj. EBITDA margin

17.1%

Animal Health segment growth (Q3)

+13% YoY

account_tree

Business model — Diversified animal health platform

Three-segment animal health and nutrition franchise, repositioned for scale via Zoetis MFA bolt-on

Phibro is a global, vertically integrated developer/manufacturer of medicated feed additives (MFAs), vaccines, nutritional specialties and mineral nutrition products for production animals (poultry, swine, cattle, aquaculture) and companion animals. The Oct 2024 acquisition of Zoetis' MFA portfolio for $297M effectively doubled its core franchise and added complementary water-soluble products — contributed $175M to sales in the last six months. Strategy now centers on (i) cross-selling Zoetis-MFA SKUs through the legacy Phibro distribution network, (ii) scaling the vaccines pipeline (e.g., Mhyosphere PCV ID swine vaccine), and (iii) deleveraging from 3.3x to ≤2.5x net debt/EBITDA by FY28. The model is asset-medium with mature ~17% EBITDA margins (vs Zoetis ~38%) — re-rating is contingent on margin expansion and Brazil regulatory clarification.

Animal Health ~$1,220M FY26E (~83% rev) 🟢 ramping (+13% Q3) MFAs, vaccines, nutritional specialties. Core franchise — beneficiary of Zoetis-MFA scale and Mhyosphere vaccine pipeline. GM target ~38%. Brazil MFA reset is the single biggest threat to organic growth. Mineral Nutrition ~$175M FY26E (~12% rev) 🟡 commodity-stable Trace mineral premixes (copper, zinc, manganese). Commodity-style; thin margins (~8% EBITDA). Anchor for relationships with feed mills — not a value driver but a sticky retention asset. Performance Products ~$72M FY26E (~5% rev) 🟡 niche-stable Specialty chemicals for personal-care and industrial markets. Non-strategic — periodic strategic review candidate. Low single-digit growth, ~10% segment EBITDA margin.

gavel

Legal, regulatory and risk analysis

Brazil antimicrobial framework change

High

May 2026 Brazilian regulatory reset on antimicrobial use forced Phibro to reassess LatAm MFA strategy. Direct revenue at risk: estimated $30–60M. Triggered the −42% drawdown. Resolution timing unclear — likely 12–18 months.

Net leverage 3.3x with $25M H1 interest expense

Moderate

$731M total debt post-Zoetis-MFA financing. Interest expense +35% YoY. Covenant cushion 1.45x to 4.75x limit — adequate but not generous if EBITDA disappoints. Deleveraging is the explicit capital allocation priority.

Zoetis-MFA integration execution

Moderate

$297M acquisition closed Oct 2024 — integration ongoing through FY26. Synergy ramp delayed could mean FY26 EBITDA at low end of guidance. Cross-selling risk: customer churn during platform consolidation.

FDA antimicrobial scrutiny (US)

Moderate

Phibro has ongoing legal proceedings with FDA over MFA usage in swine (Court of Appeals filings, 2024). Adverse ruling would impair US MFA franchise. Slow-burn risk — not imminent.

Persistent insider selling (CEO-linked)

Moderate

CEO Jack Bendheim and BFI Co. LLC sold ~$3–4M+ in shares over the last 12 months under 10b5-1 plans. Programmatic but signaling — at minimum, no insider conviction at current levels.

Dual-class share structure

Moderate

Class B shares (Bendheim family) carry super-voting rights. Public Class A shareholders have limited governance leverage. No M&A defense risk but minority protection is weak.

FY26 guidance raised on May 6, 2026

Positive

Net sales raised to $1,460–1,475M (from $1,450M low end); adj. EBITDA $247–255M; adj. EPS $2.98–3.10. The beat-and-raise validates the Zoetis-MFA accretion thesis even under emerging Brazil headwinds.

Secular animal-health tailwind

Positive

Global protein demand + farm-to-fork productivity push = mid-single-digit volume tailwind. Vaccines/specialty nutrition outpacing legacy MFAs — Phibro's mix shifting in the right direction.

article

SWOT analysis

Strengths

+Top-5 global MFA producer with diversified customer base across 65+ countries
+Zoetis-MFA acquisition doubled the core franchise — accretive from day one
+FY26E adj. EBITDA $251M up from $132M in FY24 (+90% in 2 years)
+Stable cash generation supports $0.12/q dividend; >20 consecutive years

Weaknesses

−17% EBITDA margin trails Zoetis (~38%) and Elanco (~20%) — mix-disadvantaged
−3.3x net leverage limits capital flexibility for further M&A
−Heavy reliance on MFAs (~50% of Animal Health) — regulatory-exposed
−Dual-class governance reduces minority shareholder influence

Opportunities

→Vaccines pipeline (Mhyosphere PCV ID for swine) — higher-margin growth vector
→Deleveraging to ≤2.5x by FY28 unlocks multiple expansion + M&A optionality
→Asia-Pacific aquaculture and companion animal expansion
→Performance Products divestiture would simplify equity story

Threats

!Brazil antimicrobial framework reset — direct $30–60M revenue exposure
!FDA appellate ruling on swine MFAs (pending) could be material adverse
!Persistent insider selling pressuring sentiment
!Higher-for-longer rates magnify $731M debt servicing cost

article

Summary by assessment area

🟢 Financial profile — Solid

EBITDA $251M FY26E (+27% YoY)
Margin expansion +90 bps to 17.1%
Adequate liquidity $274M (cash + undrawn)
Dividend $0.12/q sustainable at current EBITDA

🟡 Risk profile — Moderate

Brazil regulatory reset is the binding constraint
3.3x leverage manageable but not comfortable
Insider selling cumulative ~$3–4M last 12M
FDA legal proceedings on swine MFAs ongoing

🔵 Valuation — Discounted

8.2x EV/EBITDA fw vs 11–16x peer range
Base FV $45 implies +31% upside; weighted $43.4
Risk/reward 2.7:1 (bull +62% / bear −23%)
Citi $44 + consensus $42.40 align with base case

2026-08-26 earnings

Q4 FY26 / Full-Year Earnings Release

short-term Impact: High Direction: Binary

First print after Brazil regulatory shock. Watch: revised FY27 outlook, Brazil quantification, deleveraging path. Beat = sentiment reset; miss = bear case validated.

2026-09-30 regulatory

Brazil antimicrobial framework — final scope

medium-term Impact: High Direction: Binary

Quantifies the LatAm revenue exposure ($30–60M est.). Narrower scope = re-rating catalyst; broader scope = bear case acceleration. Single biggest swing factor for FY27 EBITDA.

2026-09-15 guidance

FY27 Guidance + Capital Allocation Update

medium-term Impact: High Direction: Bullish

Expected formal FY27 outlook with deleveraging trajectory. Clean path to ≤2.5x net leverage by FY28 would justify multiple expansion toward 10–11x EV/EBITDA.

2026-11-30 regulatory

FDA appellate ruling on US porcine MFA usage

medium-term Impact: Medium Direction: Binary

Phibro-FDA litigation over swine antimicrobial labeling. Adverse ruling would compress US MFA franchise; favorable removes a slow-burn overhang.

2026-12-31 product

Mhyosphere PCV ID swine vaccine — international ramp

medium-term Impact: Medium Direction: Bullish

Higher-margin (~50% GM) vaccine product launching in additional markets. Demonstrates mix-shift away from commodity MFAs toward specialty — supports the margin-expansion thesis.

2027-04-30 capital_markets

Term Loan B / Senior Credit Facility refinancing

long-term Impact: Medium Direction: Neutral

Eventual rollover of Zoetis-MFA acquisition debt. Outcome depends on rate environment and leverage trajectory. Successful refi at lower spreads = ~$5–8M annual interest savings.

2026-11-04 earnings

Q1 FY27 Earnings Release

medium-term Impact: High Direction: Binary

First quarter under FY27 guidance. Critical test of organic growth ex-Zoetis-MFA accretion (LapZ effect kicks in). Animal Health segment trajectory will tell whether the +13% is sustainable or one-off.

2026-08-05 capital_markets

Next quarterly dividend declaration ($0.12/sh)

short-term Impact: Low Direction: Neutral

Routine dividend continuation expected. A cut would signal serious cash pressure — current payout is well-covered at ~$20M/yr vs $251M EBITDA. No cut expected.

Sources & Disclaimer

Sources: PAHC 8-K (May 6, 2026 — Q3 FY26 earnings), 10-Q (Mar 31, 2026), Form 4 filings (BFI Co. LLC / J. Bendheim May 5–7, 2026), Stocktitan, Investing.com, Yahoo Finance, Trefis, Simply Wall St (May 13, 2026), MarketBeat, TipRanks, GuruFocus (Citigroup target Jun 14, 2026), StockAnalysis. Market data (May 18, 2026 — last close May 15, 2026 verified across ≥2 sources): PAHC ~$34.37, market cap ~$1.39B, 52W: $19.00–$60.08, 40.53M shares outstanding. Short interest: 5.9% of float (1.2M shares, up +10.3% MoM). FY26 adj. EBITDA guidance: $247–255M (raised May 6, 2026 from $245–250M). Analyst consensus target: $42.40 (MarketBeat, May 2026). ⚠️ Not investment advice. This document is for informational purposes only and does not constitute financial or investment advice.